STOCK TITAN

Senti Biosciences: Bayer entities report 6.9% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Senti Biosciences Holdings, Inc. is the issuer in an amended ownership report in which Bayer HealthCare LLC, Bayer US Holding LLC, and Priyal Patel each report beneficial ownership of 6,142,848 shares, or 6.90% of its common stock. The reported amount includes 3,333,000 shares issuable under a warrant exercisable in full within 60 days. Each reporting person reports shared voting and dispositive power and disclaims beneficial ownership except for shares owned of record. The 6.90% calculation uses 85,706,263 shares outstanding as of October 30, 2026, as reported by the issuer.

Filing Explained

This amendment is Schedule 13D, following a Nov. 13 Schedule 13G/A; the supplied definition describes 13D as the category for holders who may seek to influence control, unlike passive-holder 13G.

Sources and calculations
Beneficial ownership reported 6,142,848 shares Reported separately by each reporting person; includes shares underlying a warrant.
Reported ownership percentage 6.90% Reported by each reporting person.
Shares underlying warrant 3,333,000 shares Included in the reported ownership amount; the warrant is exercisable in full within 60 days.
Issuer common shares outstanding 85,706,263 shares As of October 30, 2026; used in the reported ownership-percentage calculation.
beneficial ownership regulatory
"Each Reporting Person disclaims beneficial ownership"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting power regulatory
"Shared Voting Power 6,142,848.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"Shared Dispositive Power 6,142,848.00"
Warrant technical
"the Warrant that is exercisable in full within 60 days"
A warrant is a time-limited financial contract that gives its holder the right to buy a company's shares at a set price before a specified date, like a coupon that lets you purchase stock at a fixed discount for a limited time. It matters to investors because warrants offer leveraged exposure to a stock’s upside and can dilute existing shareholders if exercised, so they affect potential gains and the company’s outstanding share count.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership did Bayer HealthCare LLC, Bayer US Holding LLC, and Priyal Patel report in SNTI?

Each reported beneficial ownership of 6,142,848 shares, or 6.90% of SNTI common stock. The reported amount includes shares underlying a warrant.

Does the reported SNTI ownership include warrant shares?

Yes. It includes 3,333,000 shares issuable under a warrant exercisable in full within 60 days.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





816944102

(CUSIP Number)
Bayer HealthCare LLC
100 Bayer Boulevard,
Whippany, NJ, 07981
862-404-3000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
11/16/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D




Comment for Type of Reporting Person:
The amounts reported in rows 8, 10 and 11 herein include the number of shares of Issuer Common Stock that would be issuable upon exercise in full of the warrant for Common Stock held by Bayer HealthCare LLC (the "Warrant"). The amount included in row 13 herein includes 3,333,000 shares of Issuer Common Stock underlying the Warrant that is exercisable in full within 60 days of the date of this filing.


SCHEDULE 13D




Comment for Type of Reporting Person:
The amounts reported in rows 8, 10 and 11 herein include the number of shares of the Issuer Common Stock that would be issuable upon the exercise in full of the Warrant. The amount reported in row 13 herein includes 3,333,000 shares of Issuer Common Stock underlying the Warrant that is exercisable in full within 60 days of the date of this filing.


SCHEDULE 13D




Comment for Type of Reporting Person:
The amounts reported in rows 8, 10 and 11 herein include the number of shares of the Issuer Common Stock that would be issuable upon the exercise in full of the Warrant. The amount reported in row 13 herein includes 3,333,000 shares of Issuer Common Stock underlying the Warrant that is exercisable in full within 60 days of the date of this filing.


SCHEDULE 13D


Bayer HealthCare LLC
Signature:/s/ Nicholas Massey
Name/Title:Attorney-in-Fact for Priyal Patel, Chief Financial Officer
Date:11/18/2026
Bayer US Holding LLC
Signature:/s/ Nicholas Massey
Name/Title:Attorney-in-Fact for Priyal Patel, Chief Financial Officer
Date:11/18/2026
Priyal Patel
Signature:/s/ Nicholas Massey
Name/Title:Attorney-in-Fact for Priyal Patel
Date:11/18/2026

Keep reading